Two brothers who owned a pharmaceutical wholesale company were sentenced on March 13, 2026, to a combined 38 years in prison for orchestrating a complex, nationwide drug diversion scheme that harmed vulnerable HIV-positive patients, placed countless others at risk, and corrupted the supply chain for prescription drugs in the United States.
According to court documents and trial evidence, the brothers, based in Easton, Maryland, founded and owned a wholesale distributor of pharmaceutical medications. One brother served as CEO, while the other was a managing partner overseeing the company’s sales division.
Evidence presented at trial showed the brothers conspired with at least five black-market suppliers to purchase HIV drugs obtained through patient “buyback schemes” at steep discounts. One supplier testified that he bought HIV drugs from patients on the street, removed the original prescription labels, and repackaged the bottles in cardboard boxes — sometimes scavenged from trash. On one occasion, he even used a diaper box found on the street. Many bottles were dirty, unsealed, and showed signs of previous dispensing.
Pharmacies reported issues to the distributor as early as August 2020, including receiving bottles containing the wrong drugs. In one instance, a pharmacy customer sent a photo of the HIV drugs they received and warned that the medications did not meet safety standards and could pose risks to patients. Trial evidence also included an article shared between the brothers just days before that complaint, noting that such schemes “hurt individuals with HIV, cost taxpayers millions, and increase viral loads in communities.”
Despite repeated warnings, the brothers continued purchasing diverted HIV drugs and selling them to pharmacies with falsified paperwork designed to mislead both customers and regulatory agencies.
A patient who received a bottle of HIV medication purchased from a pharmacy as part of the scheme testified that it actually contained Seroquel, an anti-psychotic drug, which caused him to lose consciousness for 24 hours. Even missing a single dose of HIV medication can increase a patient’s viral load and the risk of community transmission. Another patient also ingested the wrong drug, according to trial records.
The brothers took elaborate steps to conceal their conduct. They worked with black-market suppliers without informing their director of compliance, who repeatedly raised concerns, and even involved attorneys to misrepresent information about pharmacy complaints and reporting obligations to the Food and Drug Administration (FDA). Numerous incidents of incorrect or tampered medications were never reported to the FDA.
Between April 2020 and September 2021, the brothers bought and resold more than 28,000 bottles of diverted HIV drugs. They paid over $92.8 million for these medications and sold them for a profit, billing Medicare, Medicaid, and commercial insurers.
The managing partner was sentenced to 18 years in prison, and the CEO received 20 years. Both were ordered to forfeit $21,850,000. A third co-defendant previously pleaded guilty to conspiring to commit wire fraud in connection with the scheme and was sentenced to 97 months in prison.
Compliance Perspective
Issue
US consumers rely on FDA oversight to ensure that the drugs they receive are safe and effective. Title II of the Drug Supply Chain Security Act (DSCSA) establishes steps for interoperable, electronic tracing of prescription drugs at the package level, enhancing the FDA’s ability to protect consumers from counterfeit, stolen, contaminated, or otherwise harmful medications. Drugs obtained from unlicensed or unauthorized sources may bypass FDA oversight, potentially compromising safety and effectiveness, and must be avoided in healthcare settings, where medications should only come from authorized suppliers.
Discussion Points
- Review your medication management policies to ensure they clearly define requirements for purchasing medications from licensed and authorized sources. Policies should include steps for reporting concerns, documenting compliance, and preventing unauthorized procurement. Consider collaborating with an external consultant to evaluate your policies and suggest enhancements that align with current regulatory requirements and best practices.
- Train appropriate staff on F755 Pharmacy Services requirements, including the obligation to obtain medications only from US-licensed pharmacies that dispense FDA-approved products. Ensure staff understand their responsibility to maintain this standard during medication administration. Provide education to residents and their representatives at admission and through Resident Council meetings, explaining the facility’s approved pharmacies and the safety risks of bringing medications from unauthorized sources. Med-Net Academy offers the course Medication Administration for Nurses, which reviews the nine rights of medication administration, the nurse’s responsibility to verify correct medications and doses, when to clarify concerns with prescribing and dispensing professionals, and common areas where medication errors occur.
- Audit medication inventories, procurement records, and administration logs regularly to ensure adherence to policies and regulatory standards. If discrepancies or risks are identified, take prompt corrective action. Working with a consultant can provide an objective review and help design audits or mock assessments to identify potential vulnerabilities before they result in compliance issues.
*This news alert has been prepared by Med-Net Concepts, Inc. for informational purposes only and is not intended to provide legal advice.*